PAVmed Inc (PAVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PAVmed Inc (PAVM) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-896.00K) by net assets ($25.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PAVmed Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how PAVmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PAVmed Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
PAVmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PAVmed Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kolon Global Corp
KO:003075
|
-0.036x |
|
Pure Energy Minerals Ltd
V:PE
|
-0.007x |
|
T.Krungthai Industries Public Company Limited
BK:TKT
|
0.037x |
|
BRITANNIA LIFE SCIENCES
F:L020
|
N/A |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
-0.106x |
|
ClearOne Inc
NASDAQ:CLRO
|
-0.218x |
|
Moonpig Group PLC
LSE:MOON
|
-0.276x |
|
LCK Global Kedaton
JK:LCKM
|
0.002x |
Annual Cash Flow Conversion Efficiency for PAVmed Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of PAVmed Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see PAVM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.03 Million | $-33.55 Million | 4.771x | +120.21% |
| 2023-12-31 | $-24.02 Million | $-52.04 Million | 2.167x | +133.37% |
| 2022-12-31 | $10.93 Million | $-70.98 Million | -6.492x | -1170.21% |
| 2021-12-31 | $79.42 Million | $-40.59 Million | -0.511x | -101.10% |
| 2020-12-31 | $-473.00K | $-21.91 Million | 46.330x | +1508.74% |
| 2019-12-31 | $-4.64 Million | $-13.36 Million | 2.880x | -18.85% |
| 2018-12-31 | $-2.48 Million | $-8.79 Million | 3.549x | +52.97% |
| 2017-12-31 | $-2.85 Million | $-6.61 Million | 2.320x | -83.38% |
| 2016-12-31 | $-319.07K | $-4.45 Million | 13.962x | +808.29% |
| 2015-12-31 | $633.92K | $-1.25 Million | -1.971x | -2499.63% |
| 2014-12-31 | $794.83K | $-60.27K | -0.076x | -- |
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more